Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease

Journal of Neuroscience Research

Volumn 89, Issue 9, 2011, Pages 1509-1518

  Sagredo, Onintza ^a,b   Pazos, M Ruth ^a,b   Satta, Valentina ^a,c   Ramos, José A ^a,b   Pertwee, Roger G ^d   Fernández Ruiz, Javier ^a,b  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b SCHOOL OF MEDICINE   (Spain)

^c UNIVERSITY OF CAGLIARI   (Italy)

^d UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

9 tetrahydrocannabinol; 3 nitropropionic acid; Basal ganglia; Cannabidiol; Cannabinoid receptors; Huntington's disease; Malonate; Neurodegeneration; Neuroprotection; Phytocannabinoids

Indexed keywords

3 NITROPROPIONIC ACID; 4 AMINOBUTYRIC ACID; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CALPAIN; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID DERIVATIVE; CANNABIS; COPPER ZINC SUPEROXIDE DISMUTASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MALONIC ACID; PHYTOCANNABINOID; RIMONABANT; SOMATOMEDIN B; SOMATOMEDIN C; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; HUNTINGTON CHOREA; INTOXICATION; MALE; NEUROPROTECTION; NISSL STAINING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; UPREGULATION;

ANIMALS; CANNABIDIOL; CANNABINOIDS; CAUDATE NUCLEUS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUNTINGTON DISEASE; MALE; NEOSTRIATUM; NEUROPROTECTIVE AGENTS; PHYTOTHERAPY; PLANT EXTRACTS; PUTAMEN; RATS; RATS, SPRAGUE-DAWLEY; TETRAHYDROCANNABINOL;

EID: 79960062773     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.22682     Document Type: Article

References (51)

1. Alexi T, Hughes PE, van Roon-Mom WM, Faull RL, Williams CE, Clark RG, Gluckman PD. 1999. The IGF-I amino-terminal tripeptide glycine-proline-glutamate (GPE) is neuroprotective to striatum in the quinolinic acid lesion animal model of Huntington's disease. Exp Neurol 159: 84-97.
2. Alvarez FJ, Lafuente H, Rey-Santano MC, Mielgo VE, Gastiasoro E, Rueda M, Pertwee RG, Castillo AI, Romero J, Martínez-Orgado J. 2008. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Pediatr Res 64: 653-658.
3. Bantubungi K, Jacquard C, Greco A, Pintor A, Chtarto A, Tai K, Galas MC, Tenenbaum L, Déglon N, Popoli P, Minghetti L, Brouillet E, Brotchi J, Levivier M, Schiffmann SN, Blum D. 2005. Minocycline in phenotypic models of Huntington's disease. Neurobiol Dis 18: 206-217.
4. Bizat N, Hermel JM, Boyer F, Jacquard C, Creminon C, Ouary S, Escartin C, Hantraye P, Kajewski S, Brouillet E. 2003a. Calpain is a major cell death effector in selective striatal degeneration induced in vivo by 3-nitropropionate: implications for Huntington's disease. J Neurosci 23: 5020-5030.
5. Bizat N, Hermel JMH, Humbert S, Jacquard C, Créminon C, Escartin C, Saudou F, Krajewski S, Hantraye P, Brouillet E. 2003b. In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3. J Biol Chem 278: 43245-43253.
6. Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Börner C, Benito C, Carrasco C, Diez-Zaera M, Paoletti P, Díaz-Hernández M, Ruiz C, Sendtner M, Lucas JJ, de Yébenes JG, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Ginés S, Kraus J, Fernández-Ruiz J, Galve-Roperh I, Guzmán M. 2011. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134: 119-136.
7. Boll MC, Alcaraz-Zubeldia M, Montes S, Rios C. 2008. Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 33: 1717-1723.
8. Brouillet E, Condé F, Beal MF, Hantraye P. 1999. Replicating Huntinton's disease phenotype in experimental animals. Prog Neurobiol 59: 427-468.
9. Brouillet E, Jacquard C, Bizat N, Blum D. 2005. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 95: 1521-1540.
10. Calkins MJ, Jakel RJ, Johnson DA, Chan K, Kan YW, Johnson JA. 2005. Protection from mitochondrial complex II inhibition in vitro and in vivo by Nrf2-mediated transcription. Proc Natl Acad Sci U S A 102: 244-249.
11. Calkins MJ, Townsend JA, Johnson DA, Johnson JA. 2010. Cystamine protects from 3-nitropropionic acid lesioning via induction of nf-e2 related factor 2 mediated transcription. Exp Neurol 224: 307-317.
12. Consroe P, Laguna J, Allender J, Snider S, Stern L, Sandyk R, Kennedy K, Schram K. 1991. Controlled clinical trial of cannabidiol in Huntington's disease. Pharmacol Biochem Behav 40: 701-708.
13. Curtis A, Rickards H. 2006. Nabilone could treat chorea and irritability in Huntington's disease. J Neuropsychiatry Clin Neurosci 18: 553-554.
14. Curtis A, Mitchell I, Patel S, Ives N, Rickards H. 2009. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord 24: 2254-2259.
15. Damiano M, Galvan L, Déglon N, Brouillet E. 2010. Mitochondria in Huntington's disease. Biochim Biophys Acta 1802: 52-61.
16. Fernández-Ruiz J, González S, Romero J, Ramos JA. 2005. Cannabinoids in neurodegeneration and neuroprotection. In: Mechoulam R, editor. Cannabinoids as therapeutics (MDT). Basel: Birkhaüser Verlag. p 79-109.
17. 2 receptor: a new target for controlling neural cell survival? Trends Pharmacol Sci 28: 39-45.
18. Fernández-Ruiz J, García C, Sagredo O, Gómez-Ruiz M, de Lago E. 2010. The endocannabinoid system as a target for the treatment of neuronal damage. Expert Opin Ther Targets 14: 387-404.
19. Fontaine MA, Geddes JW, Banks A, Butterfield DA. 2000. Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease. J Neurochem 75: 709-1715.
20. 9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci U S A 95: 8268-8273.
21. Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J. 2000. Neuroprotective antioxidants from marijuana. Ann N Y Acad Sci 899: 274-282.
22. Herrera-Mundo MN, Silva-Adaya D, Maldonado PD, Galvan-Arzate S, Andres-Martinez L, Perez-De La Cruz V, Pedraza-Chaverri J, Santamaria A. 2006. S-allylcysteine prevents the rat from 3-nitropropionic acid-induced hyperactivity, early markers of oxidative stress and mitochondrial dysfunction. Neurosci Res 56: 39-44.
23. Johnson CD, Davidson BL. 2010. Huntington's disease: progress toward effective disease-modifying treatments and a cure. Hum Mol Genet 19: R98-R102.
24. Kalonia H, Kumar P, Kumar A. 2010. Targeting oxidative stress attenuates malonic acid induced Huntington like behavioral and mitochondrial alterations in rats. Eur J Pharmacol 634: 46-52.
25. Lagoa R, Lopez-Sanchez C, Samhan-Arias AK, Gañan CM, Garcia-Martinez V, Gutierrez-Merino C. 2009. Kaempferol protects against rat striatal degeneration induced by 3-nitropropionic acid. J Neurochem 111: 473-487.
26. Lastres-Becker I, Hansen HH, Berrendero F, de Miguel R, Pérez-Rosado A, Manzanares J, Ramos JA, Fernández-Ruiz J. 2002. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse 44: 23-35.
27. Lastres-Becker I, de Miguel R, De Petrocellis L, Makriyannis A, Di Marzo V, Fernández-Ruiz J. 2003. Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease. J Neurochem 84: 1097-1109.
28. Lastres-Becker I, Bizat N, Boyer F, Hantraye P, Fernández-Ruiz J, Brouillet E. 2004. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Neuroreport 15: 2375-2379.
29. Lastres-Becker I, Molina-Holgado F, Ramos JA, Mechoulam R, Fernández-Ruiz J. 2005. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis 19: 96-107.
30. Manyam BV, Katz L, Hare TA, Kaniefski K, Tremblay RD. 1981. Isoniazid-induced elevation of CSF GABA levels and effects on chorea in Huntington's disease. Ann Neurol 10: 35-37.
31. 1. J Neurochem 80: 448-456.
32. Mochel F, Charles P, Seguin F, Barritault J, Coussieu C, Perin L, Le Bouc Y, Gervais C, Carcelain G, Vassault A, Feingold J, Rabier D, Durr A. 2007. Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2, e647.
33. Nam E, Lee SM, Koh SE, Joo WS, Maeng S, Im HI, Kim YS. 2005. Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum. Brain Res 1046: 90-96.
34. 2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132: 3152-3164.
35. Palkovits M, Brownstein J. 1988. Maps and guide to microdissection of the rat brain. New York: Elsevier.
36. Pazos MR, Sagredo O, Fernández-Ruiz J. 2008. The endocannabinoid system in Huntington's disease. Curr Pharm Des 14: 2317-2325.
37. Pertwee RG. 2009. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol 156: 397-411.
38. Pintor A, Tebano MT, Martire A, Grieco R, Galluzzo M, Scattoni ML, Pezzola A, Coccurello R, Felici F, Cuomo V, Piomelli D, Calamandrei G, Popoli P. 2006. The cannabinoid receptor agonist WIN 55, 212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology 51: 1004-1012.
39. Pouladi MA, Xie Y, Skotte NH, Ehrnhoefer DE, Graham RK, Kim JE, Bissada N, Yang XW, Paganetti P, Friedlander RM, Leavitt BR, Hayden MR. 2010. Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet 19: 1528-1538.
40. Roze E, Bonnet C, Betuing S, Caboche J. 2010. Huntington's disease. Adv Exp Med Biol 685: 45-63.
41. Russo E, Guy GW. 2006. A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypoth 66: 234-246.
42. Sagredo O, Ramos JA, Decio A, Mechoulam R, Fernández-Ruiz J. 2007. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci 26: 843-851.
43. 2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia 57: 1154-1167.
44. Storey E, Beal MF. 1993. Neurochemical substrates of rigidity and chorea in Huntington's disease. Brain 116: 1201-1222.
45. Tabrizi SJ, Cleeter MW, Xuereb J, Taanman JW, Cooper JM, Schapira AH. 1999. Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 45: 25-32.
46. Tadros MG, Khalifa AE, Abdel-Naim AB, Arafa HM. 2005. Neuroprotective effect of taurine in 3-nitropropionic acid-induced experimental animal model of Huntington's disease phenotype. Pharmacol Biochem Behav 82: 574-582.
47. Túnez I, Muñoz MC, Montilla P. 2005. Treatment with dehydroepiandrosterone prevents oxidative stress induced by 3-nitropropionic acid in synaptosomes. Pharmacology 74: 113-118.
48. van der Stelt M, Veldhuis WB, Maccarrone M, Bär PR, Nicolay K, Veldink GA, Di Marzo V, Vliegenthart JF. 2002. Acute neuronal injury, excitotoxicity, and the endocannabinoid system. Mol Neurobiol 26: 317-346.
49. Wright S. 2007. Cannabinoid-based medicines for neurological disorders-clinical evidence. Mol Neurobiol 36: 129-136.
50. Yang L, Calingasan NY, Wille EJ, Cormier K, Smith K, Ferrante RJ, Beal MF. 2009. Combination therapy with coenzyme Q10 and creatine produces additive neuroprotective effects in models of Parkinson's and Huntington's diseases. J Neurochem 109: 1427-1439.
51. Zuccato C, Valenza M, Cattaneo E. 2010. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 90: 905-981.